HAD-C 100
HADe007-A
General
Cell Line |
|
hPSCreg name | HADe007-A |
Cite as: | HADe007-A (RRID:CVCL_B860) |
Alternative name(s) |
HAD-C 100
|
Cell line type | Human embryonic stem cell (hESC) |
Similar lines | |
Last update | 14th April 2022 |
Notes | Cell line is GMP, xeno-free, cell-fragments derived on umbilical-cord fibroblast feeders. |
User feedback | |
Provider |
|
Generator | Hadassah University Hospital (HAD) |
Owner | Hadassah University Hospital (HAD) |
Distributors | |
Derivation country | Israel |
External Databases |
|
Cellosaurus | CVCL_B860 |
NIHhESC | NIHhESC-11-0123 |
BioSamples | SAMEA6560652 |
General Information |
|
Publications |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: not allowed
Clinical use: allowed
Commercial use: allowed
Additional restrictions:
Use in research that will not have eventual clinical applications is generally not allowed. Please be in contact with us for further discussions regarding this cell cell line. There is a matching research-grade cell line available. |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Disease associated phenotypes | no phenotypes |
Family history | No diseases |
Is the medical history available upon request? | Yes (brief summary of donors' medical history) |
Is clinical information available? | No health conditions |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA6560651 |
Ethics
Was the embryo established purely for research purposes? | No |
Have both parents consented to the use of the embryo for ESC derivation? | Yes |
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | Yes |
Alternatives to consent | Other information provided sep. |
Alternative consent approval number | 0123 |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | IRB |
Approval number | 33-26-07.02 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Hadassah ESCRO Committee |
Approval number | N/A |
hESC Derivation
Date of derivation | 2008-09-01 |
Embryo stage | Blastula with ICM and Trophoblast |
Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
PGD Embryo? |
No |
Expansion status |
5 |
ICM morphology |
A |
Trophectoderm morphology |
a |
Cell isolation | Laser |
Cell seeding | Isolated ICM |
Derived under xeno-free conditions? |
Yes |
Derivation under GMP? |
Yes |
Available as clinical grade? |
Yes |
Culture Conditions
Surface coating | Gelatin |
Feeder cells |
umbilical cord fibroblasts |
Passage method |
Enzymatically
TrypLE
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: DMEM
Main protein source: Human Serum Serum concentration: 20 % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
Alkaline Phosphatase |
Yes |
|
||||
SSEA-3 |
Yes |
|
|
|||
SSEA-4 |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
||||
TRA 1-60 |
Yes |
|
|
|||
TRA 1-81 |
Yes |
|
|
hESC Doubling Time (Potency)
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
XY Normal
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.